【摘要】 目的:观察长春瑞滨(NVB)联合洛铂(LBP)组成NL方案治疗晚期乳腺癌的疗效和不良反应。方法:从2004年1月~2005年10月,采用NVB加LBP的联合化疗方案治疗晚期乳腺癌33例,LBP30mg/m2,第1天,静脉滴注3小时;NVB25mg/m2,第1、8天,静脉滴注30分钟,21天为1周期。结果:全组33例共完成105个周期,中位3周期(2~4周期),均可评价疗效。获CR1例,PR13例,SD11例,PD8例,RR为42·4%,肿瘤控制率DCR(CR+PR+SD)为75·8%,中位缓解期为4个月(1~17个月)。主要不良反应为骨髓抑制,其中Ⅲ~Ⅳ度粒细胞减少发生率为57·6%,Ⅲ度血小板减少发生率为9·1%;非血液学毒性轻微,可以耐受。结论:洛铂联合长春瑞滨组成NL方案治疗局部晚期及转移性乳腺癌疗效较好,不良反应可以耐受,在加强支持治疗(应用造血因子)的基础上,可以考虑作为二线治疗或解救化疗方案。更多还原

【Abstract】 Objective:To evaluate the results of combination chemotherapy with Vinorelbine plus Lobaplatin(DDP)in the treatment of advanced breast cancer.Methods:From January 2004 to October 2005,33 patients with advanced breast cancer wereenrolled in this study.Vinorelbine was given at a dose 25mg/m 2 on day 1 and 8,with Lobaplatin 30mg/m 2 day1 of a 21 day cycle.Results:A total of 105 cycles of chemotherapy were given,with a median of 3 cycles per patient(range,2 to 4 cycles).The overall response rate was 42.4% with CR 3.0%.The median time of response duration was 4 months(range,1 to 17 months).The main dose-limiting toxicity was myelosuppression with grade Ⅲ and Ⅳ neutropenia being in 57.6% and grade Ⅲ thrombocytopenia in 9.1%.Non-hemotologic toxicities were modest and recoverable on discontinuation of therapy.Conclusion:This combination therapy regimen shows promising results with acceptable toxicity,and on the basis of good support treatment(the application of G-CSF),it could be considered as a therapeutic salvage treatment regimen for advanced breast cancer.更多还原